Role of Tiotropium as Step Up Therapy for Asthma

Background: To determine the role of Tiotropium as step up therapy for patients with uncontrolled asthma. Methods: In this case control study 130 patients, with diagnosis of bronchial asthma for at least 01 year and presently on step 4 treatment and still symptomatic, were included . Sixty five pat...

Full description

Bibliographic Details
Main Author: Muhammad Usman Ullah
Format: Article
Language:English
Published: Rawalpindi Medical University 2013-12-01
Series:Journal of Rawalpindi Medical College
Subjects:
Online Access:https://www.journalrmc.com/index.php/JRMC/article/view/441
id doaj-1036aaab3e4049aeae2c6f80b196cb7e
record_format Article
spelling doaj-1036aaab3e4049aeae2c6f80b196cb7e2020-11-25T03:43:51ZengRawalpindi Medical UniversityJournal of Rawalpindi Medical College1683-35621683-35702013-12-01172Role of Tiotropium as Step Up Therapy for AsthmaMuhammad Usman Ullah0Department of Medicine, Military Hospital, Rawalpindi Background: To determine the role of Tiotropium as step up therapy for patients with uncontrolled asthma. Methods: In this case control study 130 patients, with diagnosis of bronchial asthma for at least 01 year and presently on step 4 treatment and still symptomatic, were included . Sixty five patients were randomly assigned to receive Tiotropium bromide dried inhaler added to their conventional step 4 treatment, whereas 65 patients were given placebo. Patients were asked about symptomatic improvement, using mini AQLQ. Peak Expiratory Flow Rate (PEFR) was checked eight weeks after wards to document response to therapy. Results: Mean age and duration of diagnosis of asthma was 38 years and 5.1 years, respectively in cases. Mean PEFR at admission among cases was 210 l/min (± 58.35) while it was 203 l/min (± 57.32) among controls. Frequency of nocturnal awakening were 2.98 days/ week among cases and 2.88 days/ week among controls. At week 8, frequency of nocturnal symptoms was found to be 1.6 days/week among patients on Tiotropium while it was 2.13 days /week among controls. Mean PEF was 387 l/min among Tiotropium group as compared to 305 l/min. There was statistically significant improvement in symptoms and PEFR of patients on Tiotropium as compared to controls. (p value 0.004). The differences remained statistically significant after adjusting for age and gender. Conclusion: Tiotropium daily as maintenance treatment through dried inhaler in addition to at least high-dose inhaled corticosteroids combined with long acting B2 agonists offers significant potential to improve airway patency in patients with severe persistent asthma who are still symptomatic and obstructed on maximal therapy. https://www.journalrmc.com/index.php/JRMC/article/view/441AsthmaTiotropiumanticholinergic
collection DOAJ
language English
format Article
sources DOAJ
author Muhammad Usman Ullah
spellingShingle Muhammad Usman Ullah
Role of Tiotropium as Step Up Therapy for Asthma
Journal of Rawalpindi Medical College
Asthma
Tiotropium
anticholinergic
author_facet Muhammad Usman Ullah
author_sort Muhammad Usman Ullah
title Role of Tiotropium as Step Up Therapy for Asthma
title_short Role of Tiotropium as Step Up Therapy for Asthma
title_full Role of Tiotropium as Step Up Therapy for Asthma
title_fullStr Role of Tiotropium as Step Up Therapy for Asthma
title_full_unstemmed Role of Tiotropium as Step Up Therapy for Asthma
title_sort role of tiotropium as step up therapy for asthma
publisher Rawalpindi Medical University
series Journal of Rawalpindi Medical College
issn 1683-3562
1683-3570
publishDate 2013-12-01
description Background: To determine the role of Tiotropium as step up therapy for patients with uncontrolled asthma. Methods: In this case control study 130 patients, with diagnosis of bronchial asthma for at least 01 year and presently on step 4 treatment and still symptomatic, were included . Sixty five patients were randomly assigned to receive Tiotropium bromide dried inhaler added to their conventional step 4 treatment, whereas 65 patients were given placebo. Patients were asked about symptomatic improvement, using mini AQLQ. Peak Expiratory Flow Rate (PEFR) was checked eight weeks after wards to document response to therapy. Results: Mean age and duration of diagnosis of asthma was 38 years and 5.1 years, respectively in cases. Mean PEFR at admission among cases was 210 l/min (± 58.35) while it was 203 l/min (± 57.32) among controls. Frequency of nocturnal awakening were 2.98 days/ week among cases and 2.88 days/ week among controls. At week 8, frequency of nocturnal symptoms was found to be 1.6 days/week among patients on Tiotropium while it was 2.13 days /week among controls. Mean PEF was 387 l/min among Tiotropium group as compared to 305 l/min. There was statistically significant improvement in symptoms and PEFR of patients on Tiotropium as compared to controls. (p value 0.004). The differences remained statistically significant after adjusting for age and gender. Conclusion: Tiotropium daily as maintenance treatment through dried inhaler in addition to at least high-dose inhaled corticosteroids combined with long acting B2 agonists offers significant potential to improve airway patency in patients with severe persistent asthma who are still symptomatic and obstructed on maximal therapy.
topic Asthma
Tiotropium
anticholinergic
url https://www.journalrmc.com/index.php/JRMC/article/view/441
work_keys_str_mv AT muhammadusmanullah roleoftiotropiumasstepuptherapyforasthma
_version_ 1724517892217634816